These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23487849)

  • 1. Abiraterone and castration-resistant prostate cancer.
    Burki TK
    Lancet Oncol; 2013 Feb; 14(2):e48. PubMed ID: 23487849
    [No Abstract]   [Full Text] [Related]  

  • 2. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
    Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
    [No Abstract]   [Full Text] [Related]  

  • 3. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
    Salem M; Garcia JA
    Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
    Omlin A; Pezaro CJ; Zaidi S; Lorente D; Mukherji D; Bianchini D; Ferraldeschi R; Sandhu S; Dearnaley D; Parker C; Van As N; de Bono JS; Attard G
    Br J Cancer; 2013 Sep; 109(5):1079-84. PubMed ID: 23928659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone and increased survival in metastatic prostate cancer.
    Sonpavde G
    N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
    [No Abstract]   [Full Text] [Related]  

  • 7. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
    Nandha R
    J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone and increased survival in metastatic prostate cancer.
    Berruti A; Pia A; Terzolo M
    N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
    Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
    J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Castration-resistant prostate cancer: systemic therapy in 2012.
    Maluf FC; Smaletz O; Herchenhorn D
    Clinics (Sao Paulo); 2012; 67(4):389-94. PubMed ID: 22522765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pathophysiology and therapy of castration-resistant prostate cancer].
    Merseburger AS; Kuczyk MA; Wolff JM
    Urologe A; 2013 Feb; 52(2):219-25. PubMed ID: 23160609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New agents in the arsenal to fight castrate-resistant prostate cancer.
    Ezzell EE; Chang KS; George BJ
    Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.
    Pal SK; Twardowski P; Josephson DY
    Maturitas; 2009 Oct; 64(2):61-6. PubMed ID: 19733987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone in prostate cancer: a new angle to an old problem.
    Stein MN; Goodin S; Dipaola RS
    Clin Cancer Res; 2012 Apr; 18(7):1848-54. PubMed ID: 22451619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Promising on advanced cancer, several new drugs coming].
    Widmark A; Karlsson CT
    Lakartidningen; 2012 Feb 22-28; 109(8):416-9. PubMed ID: 22509668
    [No Abstract]   [Full Text] [Related]  

  • 17. [New drugs in metastatic castration-resistant prostate cancer].
    Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
    Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding treatment options for metastatic prostate cancer.
    Antonarakis ES; Eisenberger MA
    N Engl J Med; 2011 May; 364(21):2055-8. PubMed ID: 21612475
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer.
    Sartor O
    Nat Rev Clin Oncol; 2011 Aug; 8(9):515-6. PubMed ID: 21808270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.
    Ferraldeschi R; Pezaro C; Karavasilis V; de Bono J
    Annu Rev Med; 2013; 64():1-13. PubMed ID: 23020876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.